Navinta Appeals Infringement Ruling Over Naropin

Law360, New York (September 3, 2009, 1:43 PM EDT) -- Generic-drug manufacturer Navinta LLC has appealed a ruling that it is liable for infringing three patents for Abraxis BioScience Inc.'s injectable pain management drug Naropin.

In a notice filed Wednesday in the U.S. District Court for the District of New Jersey, Navinta said it was appealing to the U.S. Court of Appeals for the Federal Circuit. After a bench trial, Judge Joel A. Pisano ruled that Navinta's abbreviated new drug application infringed three Abraxis patents.

Navinta's notice states that it plans to file a motion to...
To view the full article, register now.